Praexisio dedicates to high-quality, safe and efficient personalized medicine development, including small molecule drugs, functional peptides and antibodies, at a small fraction of the standard cost. We leveraged our company co-founder’s two decades of experience in protein conformation and molecular dynamics, a newly trained AI guided by x-ray crystallographically solved structures of FDA-approved drugs complexed with their target proteins, and biochemical/ cellular experiment efficacy data with highly ranked drugs by MD-based free energy calculations which feedback to the front-end recombination of safe chemical fragments. Three new drugs have been designed and showed nanomolar efficacy with low toxicity. Prx is a total solution provider and already had co-operations with entity from academia area, hospital area, and several biomedical technology company. Integrating the company’s technology, products, and expertise/opinions of global academic leaders, we design solutions that can be implemented by our high-quality engineers and scientists.
|2021||Passed selection Merck digital innovation international proposal and entered the top nine for Deep Dive Pitch.|
|2022||Launching the drug repurposing software DrDock.|
|2022||Awarded by We, Innovators’ -Startups and entering the top 15 Pitch finalists.|
|2023||Praexisio has been selected by the NSTC to exhibit the 2023 BIO International Convention in Boston.|
|2023||Begun providing services to corporate clients. Have signed a contract with a well-known Taiwanese CDMO company.|